ADC Therapeutics Stock Analysis

ADCT -  USA Stock  

USD 15.67  0.02  0.13%

The big decline in price over the last few months for ADC Therapeutics SA could raise concerns from private investors as the firm it trading at a share price of 15.67 on 214,400 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with ADC Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.34. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from ADC Therapeutics partners.
Please continue to Trending Equities.

ADC Therapeutics Stock Analysis 

 
Refresh
The ADC Therapeutics stock analysis report makes it easy to digest most publicly released information about ADC Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. ADC Therapeutics Stock analysis module also helps to analyze the ADC Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

ADC Therapeutics Stock Analysis Notes

About 51.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.28. ADC Therapeutics had not issued any dividends in recent years. ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 208 people. For more info on ADC Therapeutics SA please contact Chris Martin at 41 21 653 02 00 or go to https://www.adctherapeutics.com.

ADC Therapeutics Quarterly Cost of Revenue

502Share

ADC Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ADC Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ADC Therapeutics SA or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
ADC Therapeutics generated a negative expected return over the last 90 days
ADC Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 16.91 M. Net Loss for the year was (251.57 M) with loss before overhead, payroll, taxes, and interest of (141.82 M).
ADC Therapeutics SA currently holds about 530.19 M in cash with (223.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.91.
ADC Therapeutics has a very weak financial position based on the latest SEC disclosures
Roughly 51.0% of the company shares are held by company insiders
Latest headline from www.marketscreener.com: ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022 - Form 6-K - marketscreener.com

ADC Therapeutics Upcoming and Recent Events

Earnings reports are used by ADC Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADC Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report17th of March 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End17th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

ADC Therapeutics Largest EPS Surprises

Earnings surprises can significantly impact ADC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-03
2021-06-30-0.86-0.95-0.0910 
2021-05-06
2021-03-31-0.905-0.670.23525 
2021-03-18
2020-12-31-0.494-0.73-0.23647 
View All Earnings Estimates

ADC Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. ADC Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that ADC Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial ADC Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.

ADC Therapeutics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as ADC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADC Therapeutics SA backward and forwards among themselves. ADC Therapeutics' institutional investor refers to the entity that pools money to purchase ADC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Fmr LlcCommon Shares7.7 M208.4 M
Redmile Group LlcCommon Shares7.5 M204.5 M
Jpmorgan Chase CoCommon Shares3.3 M88.8 M
Price T Rowe Associates IncCommon Shares2.8 M76.8 M
Alliancebernstein LpCommon Shares2.7 M72.1 M
Vantage Consulting Group IncCommon Shares1.7 M45.6 M
Grosvenor Holdings LlcCommon Shares1.5 M41.2 M
Note, although ADC Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ADC Therapeutics Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ADC Therapeutics's market, we take the total number of its shares issued and multiply it by ADC Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

ADC Therapeutics Profitablity

ADC Therapeutics' profitability indicators refer to fundamental financial ratios that showcase ADC Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, ADC Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, ADC Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of ADC Therapeutics' profitability requires more research than a typical breakdown of ADC Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.87) (0.94) 
Return on Average Equity(0.99) (1.07) 
Return on Invested Capital(3.15) (3.23) 
Return on Sales(56.88) (61.37) 

Management Efficiency

The entity has return on total asset (ROA) of (29.83) % which means that it has lost $29.83 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (89.31) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics management efficiency ratios could be used to measure how well adc therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.94 in 2022. Return on Average Equity is likely to drop to -1.07 in 2022. ADC Therapeutics Total Liabilities is comparatively stable at the moment as compared to the past year. ADC Therapeutics reported Total Liabilities of 204.92 Million in 2021. Liabilities Non Current is likely to gain to about 170.9 M in 2022, whereas Current Liabilities is likely to drop slightly above 40.4 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 5.44  4.72 
Enterprise Value over EBIT(7.20) (7.77) 
Enterprise Value over EBITDA(7.12) (7.68) 
Price to Book Value 6.09  6.06 
Tangible Assets Book Value per Share 8.16  6.91 
Enterprise Value1.7 B1.7 B
Tangible Asset Value579 M624.8 M

Technical Drivers

As of the 23rd of January, ADC Therapeutics owns the market risk adjusted performance of (2.71), and Coefficient Of Variation of (488.87). ADC Therapeutics SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We were able to break down nineteen technical drivers for ADC Therapeutics, which can be compared to its peers in the sector. Please confirm ADC Therapeutics coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if ADC Therapeutics SA is priced adequately, providing market reflects its prevailing price of 15.67 per share. Given that ADC Therapeutics has jensen alpha of (0.68), we suggest you to validate ADC Therapeutics's latest market performance to make sure the company can sustain itself at some future date.

ADC Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of ADC Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

ADC Therapeutics Predictive Daily Indicators

ADC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ADC Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

ADC Therapeutics Forecast Models

ADC Therapeutics time-series forecasting models is one of many ADC Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ADC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About ADC Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how ADC Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ADC Therapeutics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as ADC Therapeutics. By using and applying ADC Therapeutics Stock analysis, traders can create a robust methodology for identifying ADC Therapeutics entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(43.88) (47.35) 
Gross Margin 0.90  0.89 
Profit Margin(44.80) (48.34) 
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 208 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ADC Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Please continue to Trending Equities. Note that the ADC Therapeutics information on this page should be used as a complementary analysis to other ADC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for ADC Therapeutics Stock analysis

When running ADC Therapeutics price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is ADC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADC Therapeutics. If investors know ADC Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ADC Therapeutics is measured differently than its book value, which is the value of ADC Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of ADC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ADC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADC Therapeutics' market value can be influenced by many factors that don't directly affect ADC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADC Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.